Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ib/II study of oral HTMC0435 tablets plus temozolomide in recurrent small cell lung cancer
CTR20222504Phase 2Active
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HTMC0435 in small cell lung cancer (SCLC), solid neoplasms, sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Started Oct 2022; status: active.
02
Drugs
HTMC0435
03
Conditions
small cell lung cancer (SCLC)solid neoplasms
Beyond the preview
Go deeper on CTR20222504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222504.